Currentsierra health and lifePolicy 2026T0560KK

Cell‑Free Fetal DNA Testing

Defines coverage and medical necessity criteria for prenatal cell-free fetal DNA testing for UnitedHealthcare Commercial and Individual Exchange members, including indications such as RhD genotyping and screening for common fetal aneuploidies. Affects providers ordering prenatal genetic screening and diagnostic testing.

Policy Summary

Payersierra health and life

PolicyCell‑Free Fetal DNA Testing

Policy CodePolicy 2026T0560KK

Change TypeTemplate update (no material clinical changes)

Effective DateJan 1, 2026

Next Review DateN/A

Key ActionOffer diagnostic invasive testing when indicated and document if declined before considering cfDNA for RhD genotyping.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Trisomies 21,18,13 + SCAsPrimary conditions considered proven for cfDNA screening

Sens 100% / Spec 99.3%RhD genotyping performance (validation)

0.07–0.13PPV range for RATs (pooled)

4.9%PPV for RATs (Zhang et al.)

01/01/2026Policy effective date

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Medical Necessity

RhD/alloimmunization testing

Covered when ALL of the following are met

Primary coverage for alloimmunization/RhD: The individual undergoing testing is alloimmunized or at risk for alloimmunization due to maternal RhD status or presence of red cell antigen antibodies

Paternal genotype condition: Paternal genotyping shows heterozygosity for RhD or paternal RhD status is unknown

Invasive testing offered and declined: Indicated invasive diagnostic testing (e.g., amniocentesis, CVS) for fetal genotyping has been offered and declined

Unproven / Not medically necessary indications

Not covered / considered unproven

Expanded or genome-wide testing: Genome-wide or exome-wide screening and expanded cfDNA panels beyond trisomies 21, 18, 13, and sex chromosome aneuploidy

Examples: MaterniT Genome; expanded panels

Twin zygosity sole purpose: Testing performed solely for determining twin zygosity

Microdeletions/CNVs: Screening for microdeletions, microduplications, or copy number variations (routine population screening)

Policy states insufficient evidence for routine screening; see CNV evidence summaries

Single gene disorders: Screening for single-gene disorders via cfDNA (routine population use)

ACOG notes insufficient evidence to support routine single-gene cfDNA screening

Coverage stance for expanded cfDNA applications

Covered only with established evidence and confirmatory testing requirements; other expanded cfDNA uses remain insufficiently supported

Standard cfDNA for common trisomies/SCAs: Standard cfDNA screening for trisomy 21, 18, 13 and sex chromosome aneuploidies has demonstrated high sensitivity and specificity and established clinical utility

Positive screening results require diagnostic confirmation (CVS or amniocentesis)

Expanded genome-wide / CNV / rare aneuploidy screening: Genome-wide/CNV/RAT screening evidence is limited with variable and often low PPVs and increased false positives (placental mosaicism); positive results require invasive diagnostic confirmation and clinical utility for routine screening is unproven

Further validation studies required; current evidence does not support routine use

Targeted 22q11.2 screening: Targeted screening for 22q11.2 may show high PPV in some assay-specific cohorts but sensitivity and prevalence limitations restrict generalization; positive screens require diagnostic confirmation and counseling

Some studies report high PPV in selected cohorts but additional sensitivity/validation data needed

ACMG-based coverage guidance

Coverage stance and recommendations per ACMG (as summarized):

ACMG_recommendations: ACMG recommends prenatal cfDNA screening over traditional screening for trisomies 13, 18, and 21 in singleton and twin pregnancies; recommends offering cfDNA screening for sex chromosome aneuploidies; suggests offering cfDNA screening for 22q11.2 deletion syndrome (conditional); insufficient evidence to recommend routine screening for CNVs other than 22q11.2 or to recommend for/against screening for rare autosomal trisomies

Strong recommendations for common trisomies; conditional recommendation for 22q11.2; no recommendation for other CNVs or RATs

Covered indications per professional society guidance

Covered when clinical use aligns with professional society recommendations:

Primary indications: Prenatal cfDNA screening for fetal trisomies 13, 18, and 21 is recommended over traditional screening methods for singleton pregnancies and is recommended for twin pregnancies (with counseling about limitations)

Supported by ACMG (strong) and ACOG/SMFM guidance

Sex chromosome aneuploidy (SCA): Screening for sex chromosome aneuploidies may be offered alongside autosomal aneuploidy screening with specific pretest counseling and consent

ISPD and ACMG support offering SCA screening with counseling

22q11.2 microdeletion: Targeted cfDNA screening for 22q11.2 deletion syndrome may be offered/considered (ACMG suggests offering; conditional recommendation) but routine screening for other CNVs is not recommended

If offered, diagnostic confirmation and counseling pathways must be in place

Cell‑free fetal DNA (cfDNA) screening for rare autosomal trisomies (RATs) and many other expanded genome‑wide indications remains an early‑stage application with limited evidence and a high rate of false positives. Large cohort and systematic reports have documented low positive predictive values and frequent discordance between cfDNA high‑risk calls for RATs and confirmatory invasive testing, often reflecting placental mosaicism rather than true fetal trisomy. As a result, these expanded uses are considered investigational or unproven and are not supported as routine screening at this time.

Current evidence does not support routine use of cfDNA for prenatal exome/genome sequencing or population‑level screening for microdeletions, CNVs, or RATs. Published validation and modeling studies report variable sensitivity and specificity depending on assay design and CNV size, and incremental detection compared with chromosomal microarray is small; further prospective validation is needed before these approaches can be recommended for routine population screening.

Routine cfDNA screening for copy number variants (CNVs) other than targeted 22q11.2 deletion screening is not currently supported by sufficient evidence. Studies and clinical utility reviews note variable positive predictive values and a high false positive rate for nonsyndromic CNVs; professional guidance (ACMG) states there is insufficient evidence to recommend routine screening for CNVs beyond 22q11.2.

Genome‑wide or expanded cfDNA screening approaches that aim to detect CNVs, microdeletions beyond 22q11.2, or other genome‑wide abnormalities are not recommended for routine population screening. The evidence base shows variable performance across platforms, low prevalence of many targeted conditions, and an elevated risk of false positives driven in part by placental mosaicism; confirmatory invasive diagnostic testing is required for any positive genome‑wide result.

Policy statements in this document are interpretive guidance and must be applied in the context of the member‑specific benefit plan and any applicable federal or state mandates. If plan terms differ from this policy, the member‑specific benefit plan governs coverage decisions; providers should verify benefits and prior authorization requirements before ordering tests.

Cell‑free fetal DNA testing using maternal plasma is considered unproven and not medically necessary for indications beyond screening for the established aneuploidies (trisomies 21, 18, 13 and sex chromosome aneuploidies). cfDNA is a screening tool only — it cannot definitively diagnose fetal genetic conditions; diagnostic confirmation requires invasive testing (CVS or amniocentesis).

Screening for rare autosomal aneuploidies (RAAs/RATs) and other genome‑wide abnormalities by cfDNA in unselected populations has not demonstrated clinical utility. Systematic and cohort evaluations report low detection rates, low positive predictive values, and frequent false positives, and current evidence is insufficient to support routine population screening for these entities.

Specifically for rare autosomal trisomies (RATs), multiple studies and clinical utility evaluations have found inadequate clinically relevant evidence to support routine prenatal cfDNA screening. Reported PPVs are low and many high‑risk cfDNA calls for RATs are not confirmed on invasive diagnostic testing, limiting their utility for routine prenatal screening.

Single‑gene cfDNA screening methods (for example, assays intended to detect paternally inherited or relative mutation dosage variants) are not recommended for broad population use because current evidence does not establish sufficient analytic and clinical validity or predictive values. These approaches may be reasonable only in specialized high‑risk contexts with appropriate validation, parental molecular data, and genetic counseling.

Covered Indications for cfDNA Testing

Noninvasive fetal RhD genotyping in RhD-negative pregnant individuals

Noninvasive fetal RhD genotyping is covered when ALL of the following are met:

Maternal RhD status: Pregnant individual is RhD-negative or has documented red cell antigen antibodies indicating alloimmunization

Paternal genotype condition: Paternal genotyping demonstrates heterozygosity for RhD or paternal RhD status is unknown

Invasive testing offered and declined: Invasive diagnostic testing (e.g., amniocentesis, CVS) for fetal genotyping has been offered and was declined by the patient

If invasive testing is accepted, diagnostic testing remains the definitive method

Assay performance and timing:

Coding, Code Lists, and Test Performance

Applicable PLA Codes (part 1)CPT

0060U	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood.
0488U	Obstetrics (fetal antigen noninvasive prenatal test), cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected.
0489U	Obstetrics (single-gene noninvasive prenatal test), cell-free DNA sequence analysis of 1 or more targets (e.g., CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition (e.g., cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia)

Applicable PLA/CPT Codes (part 2)CPT

0494U	Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative.
0536U	Red blood cell antigen (fetal RhD), PCR analysis of exon 4 of RHD gene and housekeeping control gene GAPDH from whole blood in pregnant individuals at 10+ weeks gestation known to be RhD negative, reported as fetal RhD status.
81422	Fetal chromosomal microdeletion(s) genomic sequence analysis (e.g., DiGeorge syndrome, Cri-du- chat syndrome), circulating cell-free fetal DNA in maternal blood.
81479	Unlisted molecular pathology procedure

Covered CPT Codesmixed

No codes listed

Earliest gestational age for screening

Earliest gestational age for cfDNA screeningAs early as 10 weeks gestation

Clinical implicationScreening tests using cfDNA may be performed beginning at 10 weeks gestation; positive screens require diagnostic confirmation via CVS or amniocentesis

Test types referencedApplies to prenatal cfDNA screening for common aneuploidies and some targeted assays described in the policy

RhD NGS testing performance threshold reported

Reported performance thresholdAccuracy reported beginning at 9 weeks gestation in cited NGS-based RhD validation study (sensitivity 100%, specificity 99.3%)

Study cohort

Provider Responsibilities, Counseling, and Prior Authorization

Prior Authorization

Prior Authorization, Coding, and Documentation Expectations

The following provider responsibilities, documentation expectations, and prior-authorization considerations apply when ordering or managing cell-free fetal DNA (cfDNA) testing. Verify member benefits and prior authorization requirements before ordering; inclusion of codes in policy is for reference only and does not guarantee coverage.

Applicable CPT/PLA codes are listed in this policy for reference (e.g., 0060U, 0488U, 0489U, 0494U, 0536U, 0536U, 81422, 81479). Listing of a code does not imply coverage or payment — check the member-specific benefit plan.
Prior authorization may be required for certain cfDNA assays (including expanded, genome-wide, or single-gene NIPT, and some fetal antigen assays). Providers should confirm prior authorization requirements with the member’s plan before ordering.
When expanded or genome-wide cfDNA assays are ordered (e.g., testing that attempts to detect CNVs, microdeletions, RATs, single gene disorders, or other conditions beyond trisomies 21/18/13 and common sex chromosome aneuploidies), documentation that pre-test genetic counseling occurred and the specific clinical indication for expanded testing should be included in the medical record.
When ordering cfDNA for fetal RhD genotyping or other fetal red-cell antigen testing, verify whether plan coverage is subject to clinical criteria and/or cost-effectiveness thresholds (e.g., as noted by NICE for RhD-directed anti-D prophylaxis).
Providers should be prepared to provide medical-record documentation (clinic notes, counseling documentation, ultrasound findings, prior serum screening results, paternal genotype when relevant, and any declined invasive testing) to support medical necessity determinations.

Not Covered and Experimental Uses

Testing for twin zygosity, genome‑wide/exome‑wide screening, expanded cfDNA panels, microdeletion/CNV screening (beyond targeted indications), and single‑gene disorders using cfDNA are considered not covered / unproven. Inclusion of procedure codes or assay names in reference lists does not imply coverage; providers must confirm medical necessity per the member plan.

Routine use of cfDNA for prenatal exome/genome sequencing or population screening for microdeletions, CNVs, or RATs is not supported by the current evidence base and is therefore not covered as standard practice.

Routine cfDNA screening for CNVs other than targeted 22q11.2 deletion testing is not covered given insufficient evidence of consistent performance and clinical utility across populations and platforms.

Routine genome‑wide cfDNA screening for CNVs beyond 22q11.2, routine screening for RATs, and population single‑gene cfDNA screening are not supported and therefore not covered by this policy in the absence of substantive, validated evidence of clinical benefit.

Additional items not explicitly listed here may be considered not covered if they lack peer‑reviewed evidence of analytic validity, clinical validity, and clinical utility; coverage decisions should reference the member‑specific benefit plan and applicable mandates.

Other unproven or emerging cfDNA applications will be evaluated as evidence becomes available; until then they may remain categorized as investigational or not covered per plan rules and clinical judgment.

Eligibility and Preconditions for Testing

For many single‑gene noninvasive prenatal diagnosis (NIPD) methods (for example, relative haplotype dosage approaches), accurate interpretation requires a known family history, a confirmed molecular diagnosis in the affected family member, and access to reference samples for phasing. These prerequisites are essential for assay validity and are typically required before these targeted tests can be considered clinically appropriate.

The policy does not define additional formal top‑level eligibility nodes in this extract; specific eligibility criteria depend on the test type and the member‑specific benefit plan. Refer to detailed policy sections and plan documents for complete requirements.

No additional top‑level eligibility criteria are specified in this summary extract; coverage determinations rely on the combination of clinical indication, supporting evidence, and member plan rules.

When cfDNA is used for single‑gene or highly targeted NIPD (for example, RHDO‑based tests), prior knowledge such as a parental molecular diagnosis, a documented family history of the disorder, and available reference samples for phasing are often required to ensure accurate fetal genotype inference.

Targeted NIPD methods depend on preexisting molecular information; absence of parental or family data limits analytic interpretation and is generally considered a contraindication to routine population screening with these methods.

Providers considering single‑gene cfDNA assays should confirm that necessary parental genotyping, molecular confirmation, and any required reference samples have been obtained and documented prior to ordering the test.

Definitions and Terminology

Aneuploidy

DefinitionAneuploidy: an abnormal number of chromosomes in a human cell (includes trisomy or monosomy, e.g., trisomy 21, 13, 18)

ExamplesDown syndrome (trisomy 21), Patau syndrome (trisomy 13), Edwards syndrome (trisomy 18)

Clinical relevanceAneuploidy detection is a primary target of prenatal cfDNA screening

Cell-Free Fetal DNA

DefinitionCell-Free Fetal DNA (cffDNA or cfDNA): small fragments of fetal DNA from the placenta circulating in maternal blood used for noninvasive prenatal screening

UsageAnalyzed via NIPT/NIPS assays to assess risk for fetal aneuploidies and other genomic targets

Background and Evidence Summary

Cell‑free fetal DNA (cfDNA) fragments originating from the placenta circulate in maternal blood and can be analyzed noninvasively, with tests available as early as 10 weeks gestation. cfDNA screening identifies an increased risk for fetal aneuploidy but is not diagnostic; invasive procedures (CVS or amniocentesis) are required for definitive diagnosis.

Performance Metrics and Key Evidence

References and Guideline Sources

Selected references and professional guidance informing this policy include ACMG, ACOG/SMFM, ISPD, NICE, and multiple validation and outcome studies assessing expanded cfDNA applications. These sources are cited throughout the policy and should be consulted for detailed study methods, performance metrics, and guideline statements.

Policy Summary

Payersierra health and life

PolicyCell‑Free Fetal DNA Testing

Policy CodePolicy 2026T0560KK

Change TypeTemplate update (no material clinical changes)

Effective DateJan 1, 2026

Next Review DateN/A

Key ActionOffer diagnostic invasive testing when indicated and document if declined before considering cfDNA for RhD genotyping.

SourceLink

On This Page

Fetal antigen testing other than RhD:

cfDNA-based fetal antigen status testing for antigens other than RhD

Considered unproven/insufficient evidence

No-call/uninterpretable results: Patients with no-reportable or uninterpretable cfDNA results should receive genetic counseling, comprehensive ultrasound evaluation, and be offered diagnostic testing

ISPD/ACOG recommend established pathways for no-call management

Fetal RHD and selected antigen testing: cfDNA testing for fetal RHD genotype may be used to guide antenatal anti-D prophylaxis decisions (implementation may be cost-dependent) and can be reasonable when invasive testing is declined

NICE recommends RhD cfDNA use dependent on cost-effectiveness; ACOG supports use among select alloimmunized patients who decline invasive testing

Use of validated cfDNA assays with demonstrated high sensitivity/specificity and appropriate gestational age performance (reported accuracy beginning at ~9 weeks in validation studies)

Refer to test-specific validation (e.g., Gilstrop et al. reported sensitivity 100% and specificity 99.3% beginning at 9 weeks)

Screening for common fetal aneuploidies (trisomies 21, 18, 13 and sex chromosome aneuploidies)

Screening for common fetal aneuploidies is covered as an established cfDNA screening use when performed according to guidelines:

Indication: Prenatal cfDNA screening for trisomies 21, 18, and 13 (and sex chromosome aneuploidies) for pregnant individuals as an early screening test

Testing may be offered as early as 10 weeks gestation

Screening not diagnostic: cfDNA is a screening test; positive results must be confirmed by invasive diagnostic testing (CVS or amniocentesis)

ACOG/ACMG/ISPD guidance recommends genetic counseling and diagnostic confirmation for positive screens

Singleton and twin pregnancies: cfDNA screening for these aneuploidies is recommended for singleton pregnancies and may be performed in twin pregnancies with counseling about limitations

ACMG strong recommendation; ACOG/SMFM note limitations in twin gestations

Targeted cfDNA screening for 22q11.2 or known microdeletion syndromes

Targeted cfDNA screening for certain microdeletions may be covered in select settings with counseling and confirmatory pathways:

Targeted indication: Targeted cfDNA screening for 22q11.2 deletion syndrome or other known microdeletion syndromes may be offered in select cohorts when laboratory validation and clinical pathways for confirmatory diagnostic testing are available

Studies report variable sensitivity and PPV; diagnostic confirmation required for positives

Evidence considerations: Some assay-specific studies (e.g., WGS with FF amplification, or SNP-based assays) report high PPV in selected cohorts, but sensitivity estimates and generalizability vary across studies

Performance varies by assay and cohort; laboratory-specific validation recommended

Required follow-up: Positive targeted microdeletion screens must be followed by genetic counseling and confirmatory invasive diagnostic testing (CMA/karyotype)

Clinical management should follow professional society guidance

Screening for trisomies 13, 18, 21 and sex chromosome aneuploidies in singleton and twin pregnancies

Screening for trisomies 13, 18, 21 and sex chromosome aneuploidies is supported in singleton and twin pregnancies per society guidance:

Indication: cfDNA screening for trisomies 13, 18, and 21 and sex chromosome aneuploidies in singleton pregnancies is supported and recommended over traditional screening; cfDNA may be offered for twin pregnancies with appropriate counseling

ACMG strong recommendation; ACOG/SMFM and ISPD guidance support use

Counseling and confirmatory testing: Pretest counseling, post-test counseling for positive results, and offer of diagnostic confirmation are required elements of testing pathways

22q11.2 deletion syndrome screening

ACMG conditional recommendation (moderate certainty):

Offer consideration: ACMG suggests offering cfDNA screening for 22q11.2 deletion syndrome to all pregnant individuals (conditional recommendation); clinicians should discuss benefits, limitations, and confirmatory testing pathways

Evidence moderate; counseling emphasized

Screening for fetal trisomies 21, 18, and 13 in singleton pregnancies

Covered when performed consistent with guideline recommendations:

Singleton pregnancies: Screening for fetal trisomies 21, 18, and 13 in singleton pregnancies is supported as standard cfDNA screening

Offered as early as 10 weeks; positive results require confirmatory diagnostic testing

Twin pregnancies: Screening may be offered for twin pregnancies with counseling about limitations and potential reduced performance for trisomy 13/18

Pretest counseling should include twin-specific limitations

Screening for sex chromosome aneuploidies alongside autosomal aneuploidy screening

Screening for sex chromosome aneuploidies is supported when offered with counseling:

Concurrent screening: Sex chromosome aneuploidy screening may be offered alongside autosomal aneuploidy cfDNA screening when specific pretest counseling is provided

ISPD and ACMG support offering SCA screening with counseling

Counseling requirement: Pretest counseling should cover potential findings, variable PPV, and implications of SCA detection

Offer post-test counseling and confirmatory diagnostic testing for positive results

Targeted screening for 22q11.2 deletion syndrome may be offered/considered

Targeted 22q11.2 screening may be offered/considered with appropriate pathways:

Offer/Consider: Targeted screening for 22q11.2 deletion syndrome may be offered (ACMG suggests offering) in contexts with validated assays, available confirmatory testing, and counseling resources

Laboratory-specific performance and cohort characteristics should inform use

Follow-up: Positive results require genetic counseling and invasive diagnostic confirmation (CMA) to establish fetal status

Fetal RHD genotyping to guide anti-D prophylaxis in RhD-negative pregnant individuals

Fetal RHD genotyping to guide anti-D prophylaxis may be implemented with consideration of cost-effectiveness and clinical context:

Indication: Fetal RHD genotyping via cfDNA may be used to guide antenatal anti-D immunoglobulin prophylaxis decisions in RhD-negative pregnant individuals

NICE recommends use dependent on cost thresholds; ACOG supports reasonable use among selected alloimmunized patients

Testing pathway: When invasive testing is offered and declined, validated cfDNA RhD testing may be used as an alternative with appropriate counseling and documentation

Assay validation (sensitivity/specificity) and gestational age performance should be considered

Screening for common fetal aneuploidies and certain expanded indications

Screening for common fetal aneuploidies and certain expanded indications may be covered per validation and guideline literature; final determinations depend on member-specific benefit plans:

Established aneuploidy screening: cfDNA screening for common fetal aneuploidies (trisomies 21, 18, 13 and SCAs) is an established covered indication when performed per guidelines

Positive results require diagnostic confirmation

Selected expanded indications: Certain expanded indications (e.g., targeted 22q11.2 screening, fetal RhD genotyping) may be covered when supported by validation data, counseling, and confirmatory testing pathways; coverage is subject to member-specific benefit plan rules

Laboratory- and plan-specific determinations required

Prospective validation cohort of 655 RhD-negative pregnant individuals with 356 RhD-positive fetuses and 297 RhD-negative fetuses

Clinical noteAuthors reported PPV 98.4% and NPV ~100% beginning at 9 weeks gestation

Gestational age limit for certain analyses

Gestational age observationsSome analyses evaluated samples as early as 9 weeks gestation; certain study workflows evaluated limited assays only above specified FF thresholds

Study restrictionsIn selected cohorts low fetal fraction samples (e.g., FF 2.8–6.5%) were sometimes assessed only for specific paternal haplotypes or partially reported

Implication for orderingProviders should note study-specific gestational age and fetal fraction criteria when interpreting validation performance

Before relying on this policy for coverage decisions, check the member specific benefit plan document and any applicable federal or state mandates; the member plan document governs in the event of conflict.

Documentation Required

Expanded / Genome-wide cfDNA — Counseling and Documentation

Expanded cfDNA assays (including genome-wide or exome-wide approaches, CNV/microdeletion panels, and single-gene NIPT) have variable performance characteristics and may require additional documentation and counseling.

Pre-test and post-test genetic counseling is strongly recommended and generally expected when ordering expanded cfDNA testing due to implications of variable positive predictive values and downstream management.
Providers should document the clinical indication for expanded testing, evidence of counseling, and any relevant ultrasound or risk findings in the medical record at time of order.
Laboratories and clinicians should have clear clinical pathways for handling 'no-call' or uninterpretable results and for reporting and managing high-risk results from expanded panels.

Documentation Required

Confirmatory Diagnostic Testing after High-Risk or Screen-Positive cfDNA

When cfDNA results are screen-positive for rare autosomal aneuploidies (RATs), copy number variants (CNVs), microdeletions, or other nonroutine findings, confirmatory diagnostic testing should be offered and documented.

Offer invasive diagnostic confirmation (chorionic villus sampling or amniocentesis with karyotype and/or chromosomal microarray) for screen-positive RATs or CNVs and document that counseling and diagnostic options were provided.
If invasive diagnostic testing is offered but declined, document that the diagnostic option was offered and the patient’s informed decision to decline; in some contexts (e.g., RhD alloimmunization), cfDNA may be considered if invasive testing was offered and declined.
Providers should be prepared to supply diagnostic confirmation (CMA, karyotype, or other appropriate testing) results when available to support outcome assessment and any appeals.

Documentation Required

No-Call / Low Fetal Fraction — Counseling and Follow-up

Management of 'no-call' or low fetal fraction results requires specific clinical follow-up and documentation.

A 'no-call' result is associated with an increased risk of fetal aneuploidy and adverse pregnancy outcomes; providers should offer genetic counseling and document the discussion.
Clinical pathways for 'no-call' results should include consideration of detailed ultrasound, repeat cfDNA (if appropriate), alternative screening tests, or direct offer of invasive diagnostic testing, and the chosen plan should be documented.
Low fetal fraction should prompt counseling about potential causes (e.g., high maternal BMI) and implications for test performance; document counseling and follow-up plans in the record.

Documentation Required

When to Offer Invasive Diagnostic Testing or Reflex sgNIPT

When fetal structural ultrasound anomalies are present, invasive diagnostic testing or reflex diagnostic strategies should be prioritized and documented.

For pregnancies with structural ultrasound anomalies (including NT ≥ 3.5 mm or other major findings), offer diagnostic testing (CVS or amniocentesis) with chromosomal microarray regardless of prior cfDNA screening results and document that this was offered.
If cfDNA was used as a contingent or follow-up screen in the setting of ultrasound anomalies, document counseling that cfDNA is a screening test and not diagnostic, and that diagnostic testing remains the preferred method to evaluate CNVs or other genomic abnormalities.
When ordering reflex single-gene NIPT (sgNIPT) or other targeted reflex testing in the setting of ultrasound anomalies, ensure and document that appropriate confirmatory testing pathways are available.

Prior Authorization

Member Benefit Verification and Medical Record Documentation

Member benefit verification and prior authorization checks are required prior to ordering cfDNA testing; medical-record documentation may be requested to substantiate coverage.

Always verify member-specific benefits and prior authorization requirements before ordering; the member-specific benefit plan language governs coverage.
Medical records (including documentation of counseling, indications, ultrasound findings, paternal genotype when relevant, and any declined invasive testing) may be required for plan review and coverage determination.
If coverage is denied, use documented counseling and offered diagnostic testing information when pursuing internal review or appeals.

Failure to provide required family history or reference specimens may render single‑gene cfDNA testing uninterpretable; such tests should only be used in well‑defined clinical scenarios with appropriate laboratory validation.

Diagnostic limitationcfDNA screening identifies increased risk but cannot definitively diagnose fetal genetic conditions; CVS or amniocentesis required for diagnosis

Twin Zygosity

DefinitionTwin zygosity: classification of twins as dizygotic (fraternal) or monozygotic (identical) based on origin of fertilization

Genetic implicationDizygotic twins share ~50% of genes like non-twin siblings; monozygotic twins originate from a single zygote

cfDNA relevanceZygosity influences interpretation of cfDNA results in multifetal pregnancies

NIPT/NIPS — screening vs diagnostic distinction

DefinitionNIPT/NIPS (Noninvasive Prenatal Testing/Screening): cfDNA-based screening methods that estimate risk for fetal genetic conditions but are not diagnostic

Action after positive screenPositive NIPT/NIPS results require confirmatory invasive diagnostic testing (CVS or amniocentesis)

ScopeIncludes screening for common autosomal trisomies and sex chromosome aneuploidies; expanded uses have variable evidence

Confined placental mosaicism

DefinitionConfined placental mosaicism: presence of aneuploid or trisomic cell lines in the placenta but not in the fetus, which can cause discordant positive cfDNA results

ImplicationCan produce false-positive cfDNA screening results and is associated with increased risk of adverse pregnancy outcomes; warrants further diagnostic evaluation

CounselingPre- and post-test counseling should address the possibility of placental mosaicism and need for invasive confirmation

CNV detection by cfDNA

DefinitionCNV detection by cfDNA: screening for microdeletions and duplications (pathogenic copy number variants) using cfDNA sequencing or genome-wide approaches

Performance variabilityTest performance varies by CNV size, assay method (SNP-based, WGS, targeted), sequencing depth, and algorithm; reported PPVs and sensitivities are variable across studies

Confirmatory testingPositive CNV/cnv-like findings require invasive diagnostic confirmation (e.g., chromosomal microarray)

No-call / insufficient fetal fraction

DefinitionNo-call / insufficient fetal fraction: a test result that cannot be reported due to low fetal fraction or other technical limitations

Common causesInsufficient fetal fraction is the most frequent reason for no-call; factors include early gestational age, high maternal BMI, vanishing twin, and assay limits

ManagementACMG/ISPD recommend pathways including repeat NIPT, detailed ultrasound, alternative screening, and offer of diagnostic testing

Microdeletion (22q11.2) screening

DefinitionMicrodeletion (22q11.2) screening: targeted cfDNA analysis to detect clinically significant deletions in the 22q11.2 region (DiGeorge/22q11.2 deletion syndrome)

Reported performanceStudy-reported sensitivity varies (e.g., Dar et al. sensitivity 75% with PPV 23.7%; updated algorithm PPV 52.6%); other studies report sensitivity up to ~90% in select cohorts

RecommendationPositive screens require diagnostic confirmation with chromosomal microarray; population-level performance limited by low prevalence and wide CIs

No-call — uninterpretable result

DefinitionNo-call (uninterpretable) result: laboratory fails to report a result, commonly due to insufficient fetal fraction

AssociationNo-call results are associated with increased risk of aneuploidy and adverse pregnancy outcomes; require counseling and offer of diagnostic testing

Laboratory roleLaboratories should validate no-call thresholds and provide clinical pathways for management and disclosure

RATs — Rare autosomal trisomies

DefinitionRare autosomal trisomies (RATs): uncommon whole-chromosome trisomies detected by cfDNA for which current evidence is limited and routine screening is not recommended

Evidence limitationsMeta-analyses report low pooled PPV (confirmed method ~0.07; extended method ~0.13) and many cfDNA-identified RATs are not confirmed in the fetus, often due to placental mosaicism

Clinical implicationScreen-positive RAT results warrant diagnostic confirmation and increased prenatal monitoring; routine population screening is unsupported

cfDNA screening terminology and uses

TerminologycfDNA, cffDNA, NIPT, and NIPS are used across guideline and validation literature to refer to cell-free fetal DNA-based noninvasive prenatal screening methods

Usage noteGuidelines (ACMG, ACOG, ISPD) and validation studies use these terms interchangeably; specific assay descriptions (SNP-based, WGS, targeted) clarify methodologic differences

Clinical takeawayUnderstanding assay-specific terminology and methodology is important for interpreting performance metrics and counseling patients